Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generics Bulletin Originals

Set Alert for Originals

Set Alert for What's Next
What's Next?

What’s Next? Five Things To Look Out For In May

This month, Eli Lilly’s Alimta blockbuster will lose patent protection in the US, while Teva – which will also publish its Q1 financial results – will see Bristol Myers Squibb begin its appeal process against a key UK ruling involving the originator’s Eliquis (apixaban) anticoagulant.

Generic Drugs Biosimilars

What’s Next? Five Things To Look Out For In April

In the month ahead, Japanese firms are set to be hit with further price cuts to their generics, while Eagle Pharmaceuticals will throw off the restraints for its Pemfexy (pemetrexed) 505(b)(2) version of Eli Lilly’s Alimta.

Biosimilars Generic Drugs

What’s Next? Five Things To Look Out For In March

This month, generic competition to several lucrative brands, not least Bristol Myers Squibb’s $8.7bn Revlimid, are set to fall to generic competition in the US. Meanwhile, Sawai is looking to close on a key deal.

Biosimilars Generic Drugs

What’s Next? Five Things To Look Out For In February

In February, key launches from Accord and Eagle are set to go ahead, while Viatris will host its delayed investor day and industry will meet in-person in Florida for the US Association for Accessible Medicines’ Access! event.

Biosimilars Generic Drugs
See All

Set Alert for Interviews
Interviews

Samsung Bioepis ‘Setting A High Bar’ For Next Wave Of Biosimilars

In the wake of parent company Samsung Biologics completing its full acquisition of Samsung Bioepis, the Korea-based biosimilars player has told Generics Bulletin that it will be a “more robust company,” as it applies more rigorous standards to replenishing its pipeline of biosimilar candidates.

Biosimilars Companies

Biosimilars Forum Calls For Further Action On Biden’s Competition Order

Generics Bulletin sits down with Biosimilars Forum executive director Julie Reed to discuss preparing the HHS for Humira biosimilars, what more the agency could do for the industry and the Forum’s priorities over the next year.

Biosimilars Market Access

Oral Humira Biosimilar Could Be A Game-Changer, Says Rani CEO

Oral delivery of biosimilars could bring significant benefits for patients as well as offering a key differentiating factor for competing developers, especially in the US adalimumab arena, Rani Therapeutics CEO Talat Imran tells Generics Bulletin.

Biosimilars Value-Added Medicines

Stampa Urges Investment In European Manufacturing

Fresh from being named as the new president of Medicines for Europe, Medichem CEO Elisabeth Stampa sets out the association’s priorities around investment in European manufacturing, as well as identifying key obstacles that must be overcome to create a sustainable environment for off-patent medicines, in an exclusive interview with Generics Bulletin.

Europe Policy
See All

Set Alert for Pricewatch UK
Pricewatch UK

Solifenacin Surges As UK Sees Huge Price Rises In April

Multiple different generics saw triple-digit-percentage price rises that led UK averages to as much as quadruple in April 2022, according to the latest figures from WaveData. Solifenacin and ibandronic acid led the month’s steepest increases.

Market Intelligence Pricing Strategies

UK Pramipexole Prices Plummet In March

Multiple presentations of pramipexole modified-release tablets saw their average UK trade prices nosedive in March, according to the latest figures from market researcher WaveData, which also revealed the reason for the dramatic declines.

Market Intelligence Pricing Strategies

Trio Of Generics See UK Prices Double In February

Three different generics saw their average UK trade price more than double in February 2022, according to the latest figures from WaveData, with losartan/hydrochlorothiazide, ascorbic acid and amoxicillin leading the month’s biggest rises.

Market Intelligence Pricing Strategies

UK Kicks Off 2022 With Celecoxib And Rizatriptan Rises

UK average trade prices for certain presentations of celecoxib and rizatriptan trebled and even quadrupled in the first month of 2022, according to the latest figures from WaveData.

Market Intelligence Pricing Strategies
See All
UsernamePublicRestriction

Register